Company / Cash & Equivalents
Centessa Pharmaceuticals plc Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$61.3M
FY2025
5-year range
$61.3M / $595.1M
FY2021-FY2025
Trend
-84.0%
vs FY2024
Sector context
#172 of 206
Health Care
What the data says
Centessa Pharmaceuticals plc's cash & equivalents of $61M is lower than 83% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 6 years, ranging from $7M in FY2020 to $595M in FY2021.
Based on SEC 10-K filings.
$61M in FY2025 with a 5-year CAGR of +53.4%.
Declined from $128M to $61M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -46.2%
- 5-Year CAGR
- +53.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 206This company $61.3M Sector average $672.3M
▼
-90.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +53.4%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 84.0% year-over-year.
- Ranks #172 out of 206 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.80 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $61.3M | -84.0% |
| FY2024 | $383.2M | +199.3% |
| FY2023 | $128.0M | -67.5% |
| FY2022 | $393.6M | -33.9% |
| FY2021 | $595.1M | +8134.1% |
| FY2020 | $7.2M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026